Clinical trials: sponsored by Sun Yat-sen University
Hormone Receptor-Positive Breast Cancer, HER2 Low Breast Carcinoma
Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
This is a single-center, open-label, randomized phase II clinical trial designed to evaluate the efficacy and safety of neoadjuvant Culmerciclib combined with aromatase inhibitor versus aromatase-inhibitor monotherapy in patients…
- Conditions
- Hormone Receptor-Positive Breast Cancer, HER2 Low Breast Carcinoma, Early-Stage Breast Cancer
- Trial name
- NCT07796880
- Testing
- Culmerciclib, Aromatase Inhibitor (AI)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nephrotic Syndrome
Super Chinese Nephrotic Syndrome Registration System (SUCCESS)
The investigators are registering all nephrotic syndrome (NS) patients regardless of the primary causes and developing a NS database in China.
- Trial name
- NCT03001934
- Testing
- No intervention
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Sun Yat-sen University
Phase 2 Study
mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer
Neoadjuvant mFOLFOXIRI plus bevacizumab may achieve tumor shrinkage and reduce micrometastases, offering a radiotherapy-free organ-preservation alternative for locally advanced rectal cancer.
- Trial name
- FOBEAR-ii (NCT07817888)
- Testing
- FOLFOXIRI + Bevacizumab
- Volunteers
- 119 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Acute-On-Chronic Liver Failure, Sepsis
Efficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis
This study aims to evaluate the efficacy and safety of the double plasma cytokine adsorption system with sequential low-dose plasma exchange (DPCAS+LPE) in patients with acute-on-chronic liver failure (ACLF) complicated by…
- Trial name
- NCT06562803
- Testing
- double plasma cytokine adsorption system with sequential low-dose plasma exchange, plasma exchange
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Keratoconus, Stable
Perceptual Learning Improve Visual Function in Patients With Keratoconus
This project aims at non-progressive keratoconus patients with unsatisfactory visual acuity corrected by spectacles, and explores the effectiveness and maintenance of visual acuity improved by perceptual learning.
- Trial name
- KPL (NCT05220904)
- Testing
- spectacles, perceptual learning
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Neuroblastoma
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.
The survival rate of recurrent and refractory neuroblastoma is low and the prognosis is poor. Apatinib mesylate is a highly selective small-molecule vasoendothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor.
- Trial name
- NCT05027386
- Testing
- Apatinib, Irinotecan, Temozolomide
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Sun Yat-sen University
Arteriosclerosis Obliterans
Outcome and Improvement of Different Treatment in Arteriosclerosis Obliterans
This study is a prospective, single-center, observational study. In this study, we aim to evaluate the clinical outcome and cost-effectiveness of different treatments of lower extremity arterial occlusive disease.
- Trial name
- NCT06485622
- Testing
- open bypass group, bare metal stent group, plain old balloon angioplasty group
- Where
- China
- Volunteers
- 400 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC
Head and Neck Squamous Cell Carcinoma (HNSCC) is the most common malignant tumor of the head and neck, accounting for 90% of head and neck malignancies, and 16% to 40% of systemic malignancies.
- Trial name
- NCT04947241
- Testing
- PD-1 inhibitor+ Gemcitabine + Cisplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
ESCC
Node-Sparing Short-Course Radiotherapy (25 Gy/5 Fractions) Combined With Chemoimmunotherapy as Neoadjuvant Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma：A Prospective Single-Arm, Phase II Study
This prospective, single-arm phase II study will evaluate the efficacy and safety of lymphatic-drainage-sparing short-course radiotherapy combined with camrelizumab and nab-paclitaxel/carboplatin as neoadjuvant treatment for…
- Trial name
- NeoSCRTIC-01 (NCT07808853)
- Testing
- Neoadjuvant SCRT + Camrelizumab + Nab-Paclitaxel/Carboplatin
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment
The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC
This is an open-label, single-arm, phase II clinical trial to explore the efficacy and safety of neoadjuvant low-dose radiotherapy combined with chemoimmunotherapy in resectable locally advanced head and neck squamous cell…
- Trial name
- NCT05343325
- Testing
- Tislelizumab, Low-dose radiotherapy
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Colorectal Cancer
Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients
BRAF-mutated colorectal cancer, primarily driven by the BRAF V600E mutation, accounts for approximately 5-10% of all colorectal cancer cases and is associated with aggressive disease progression and poor prognosis, particularly…
- Trial name
- NCT07809893
- Testing
- Ivonescimab +mFOLFOXIRI +celecoxib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Septic Shock, Acute Kidney Injury
Early Endotoxin Burden Reduction With oXiris in Septic Shock Patients Requiring CRRT
The goal of this clinical trial is to learn whether continuous renal replacement therapy (CRRT) using the oXiris filter can lower the amount of endotoxin in the blood of adults with septic shock who need CRRT.
- Trial name
- NCT07807410
- Testing
- oXiris Hemofilter
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unresectable Hepatocellular Carcinoma
Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
To evaluate the efficacy and safety of anlotinib combined with benmelstobart and HAIC as first-line treatment for unresectable hepatocellular carcinoma.
- Trial name
- ABH-uHCC (NCT07806292)
- Testing
- anlotinib combined with benmelstobart and HAIC
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Mitral Regurgitation Functional
TEER In dynaMic sEvere Functional Mitral Regurgitation (TIMER)
Functional mitral regurgitation is a highly dynamic disease. Some patients exhibit only moderate(2+) functional mitral regurgitation at rest, which deteriorates to moderate-to-severe or severe FMR(3+ or 4+) during stress-termed…
- Trial name
- NCT07197021
- Testing
- TEER, GDMT
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Sun Yat-sen University
Postoperative Acute Pain
Efficacy and Safety of Anrikefon Injection for Multimodal Postoperative Analgesia in Patients Undergoing Laparoscopic Hepatectomy
A single-center, randomized, double-blind, placebo-controlled trial design will be adopted to investigate whether Anruikefon can significantly reduce the consumption of sufentanil via PCIA pumps within 48 hours postoperatively…
- Trial name
- NCT07801183
- Testing
- Anruikefon 1 μg/kg per dose Group, Anruikefon 100 μg per dose Group, Control group
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Radiotherapy, Radiation-Induced Complications
A Prospective, Single-Arm Clinical Study of a Dietary Supplement for the Prevention of Acute Radiation-Induced Rectal Injury During Neoadjuvant Chemoradiotherapy for Rectal Cancer
This clinical study is a prospective, single-arm, single-center trial aimed at assessing the safety and efficacy of tributyrin (TB) as a dietary supplement for preventing acute radiation-induced rectal injury (ARII).
- Trial name
- NCT07802002
- Testing
- Tributyrin
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Wound
EpiSC-Enhanced Composite Grafts for Skin Reconstruction
This randomized controlled trial evaluated a single-stage treatment for full-thickness skin defects using an autologous epidermal stem cell (EpiSC)-enriched cell suspension prepared during surgery.
- Trial name
- NCT02070809
- Testing
- EpiSC-Enhanced Composite Grafting, Standard Composite Grafting
- Where
- China
- Volunteers
- 232 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Nasopharyngeal Carcinoma (NPC)
Comparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: cfDNA Methylation, EBV DNA, and Serological Double-antibodies Detection
This study focus on nasopharyngeal carcinoma, a cancer type with Chinese characteristics, analyze the early screening detection performance of nasopharyngeal carcinoma in the multi-cancer early screening model, and compare the…
- Trial name
- PROFOUND-NPC (NCT06763289)
- Where
- China
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Radiotherapy, Radiation Proctitis
Association Between Clinical Classification and Prognosis in Chronic Radiation Enteropathy
This is a prospective, observational study aimed at exploring the associations between the clinical classification of chronic radiation enteropathy and prognosis.
- Conditions
- Radiotherapy, Radiation Proctitis, Radiation Enteritis
- Trial name
- NCT07378631
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Pancreatic Cancer
TCR-T Cell Therapy on Advanced Solid Tumors
The primary aim of this study is to evaluate the efficacy of KRAS mutant antigen specific TCR-T cells in the treatment of patients with advanced solid tumors.
- Trial name
- NCT05438667
- Testing
- TCR-T therapy
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.